Patrys Limited · ASX:PAB
Patrys — Shareholder Meeting (November 2024)
18 slides from Patrys's shareholder meeting presentation, Nov 22, 2024
Slide 1: Chair's Address and CEO Presentation at Annual General Meeting
ASX & Media Release Chair's Address and CEO Presentation at Annual General Meeting Melbourne, Australia; 22 November 2024: Patrys Limited (ASX: PAB, "Patrys" or the "Company"), a therapeutic antibody development company, is pleased to release the Chair's Address and Chief Executive Officer (CEO) Pre
Slide 2: Chair's Address (continued)
This clearly was a major disappointment for the Company, the staff and the Board. Furthermore, given that there had been challenges with previous manufacturing runs of PAT-DX1, including a contamination issue that delayed the commencement of the most recent run, the Board concluded and announced in
Slide 3: Concluding Remarks
Concluding Remarks: Despite the challenges that the past Financial Year presented, Patrys' team has worked tirelessly to advance its deoxymab programs, and where required, to identify and rectify problems as they have arisen. We remain guided by both scientific and commercial inputs, always using th
Slide 4: About Patrys' deoxymabs
About Patrys’ deoxymabs Patrys has developed a new type of antibody - deoxymabs - which are attracted to cancer cells that do not have traditional cell surface markers of disease. Instead, they bind to fragments of DNA that are released from cells when they die - the rate of cell death is much highe
Slide 5: CEO Presentation, November 2024
For personal use only 2024 AGM Presentation Dr James Campbell CEO and MD 22 November 2024
Slide 6: Safe harbour statement
Safe harbour statement The following material is for general information purposes only and is not to be relied upon for the making of an investment decision. Any investment in Patrys Limited ACN 123 055 363 (Patrys) is subject to investment risk including the possibility of loss of capital invested
Slide 7: Investment summary
Investment summary Patrys’ deoxymab technology antibodies have potential for use in treating a range of indications: • Cancers with DNA damage repair mutations (alone or in combination with other therapies) • Inflammatory diseases caused by neutrophil extracellular traps (NETs) For personal use only
Slide 8: Company snapshot
Company snapshot 12 month share price performance Shares 2.1B Market cap¹ A$9.2M For personal use only Cash² A$2.6M HQ Melbourne Charmaine Gittleson (Chair) Board James Campbell (CEO & MD) Pamela Klein (NED) Mike Stork (NED) Price¹ $0.0045 Substantial Dr Dax Marcus Calder – 11.2% 12 mth high - low $
Slide 9: Board of Directors
Board of Directors Dr Charmaine Gittleson Dr Pamela M. Klein • Former Chief Medical Officer of CSL Limited • Former VP, Development at Genentech • Global expertise in drug development, • Board member of Argenx (Euronext & Nasdaq: ARGX) For personal use only clinical development, regulatory strategy
Slide 10: Year in review – clinical trial preparations
Year in review – clinical trial preparations • Significant focus on preparation activities for a Phase 1 clinical trial of PAT-DX1: • Expanding non-clinical data set continuing to support potential therapeutic applications for deoxymabs • Completed preclinical studies required to initiated clinical
Slide 11: Year in review – non-clinical research
Year in review – non-clinical research • New data from preclinical studies using deoxymabs in animal models of high- grade glioma presented at the American Association for Cancer Research (AACR) conference For personal use only • Significant expansion of understanding of mechanism of action, particu
Slide 12: Looking Ahead
For personal use only Ahead Looking
Slide 13: The path forward
The path forward... Establish partnership to further clinical development of PAT-DX1: • Comprehensive preclinical data pack – ready for clinic subject to manufacturing • Seeking industry partner with expertise and resources to progress PAT-DX1 Prioritise internal development of PAT-DX3: For personal
Slide 14: Growing understanding of the roles of NETosis in multiple pathologies
Growing understanding of the roles of NETosis in multiple pathologies Neutrophils are the most common white blood cells in the human immune system For personal use only When challenged neutrophils undergo a process in which they release sticky aggregates of DNA/protein called Neutrophil Extracellula
Slide 15: PAT-DX3 expansion opportunities in NETosis
PAT-DX3 expansion opportunities in NETosis PAT-DX3 has demonstrated several desirable properties for treating disease in which NETosis is believed to have a key role: • Inhibits human neutrophil NETosis regardless of the stimulating factor • Has no impact on the viability, cytotoxicity, or apoptosis
Slide 16: Development of PAT-DX3
Development of PAT-DX3 • PAT-DX3 o Different pharmacokinetic profile to PAT-DX1 For personal use only o Structurally more stable than PAT-DX1 o Higher manufacturing yields, simpler purification process o Crosses the blood brain barrier o Efficacy in animal models in multiple indications (cancer, inf
Slide 17: Outlook and potential catalysts
Outlook and potential catalysts License or co-development partner for PAT-DX1 For personal use only Development of PAT-DX3 for non-oncology indications (subject to availability of funding) Commence GMP manufacture of PAT-DX3 (subject to availability of funding) Strengthen balance sheet – with non-di
Slide 18: Contact
Contact Dr. James Campbell CEO and MD +61 3 9670 3273 For personal use only info@patrys.com patrys.com Patrys Limited (ASX:PAB)